This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | MicrobiomeTrials
← Back to trials NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-07-08Est. Completion: 2034-06-01
Enrollment target: 100 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Malignant Pleural Mesothelioma
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pem…
Nishinomiya, Japan Est. completion Jun 30, 2026
Mesothelioma Families
Background:
-A gene provides instructions to the body. Mutated genes can sometimes cause cancer. Germline mutations are…
Bethesda, United States Est. completion Jul 6, 2026
Phase 3
Recruiting
Unresectable Pleural Mesothelioma
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustom…
Santa Rosa, United States Est. completion Nov 16, 2028